Your search for ‘Spruson & Ferguson’ returned 1,285 results

Malaysia is drafting its first patent linkage framework for pharmaceutical products, scheduled for implementation on 1 May 2027 following CPTPP ratification. The National Pharmaceutical Regulatory Agency has released draft guidelines establishing an administrative connection between drug registration and patent status, introducing notification requirements, suspension periods, and four application categories that will fundamentally reshape how innovators and generic manufacturers navigate market entry.

Infringement of a Swiss-style claim does require the pharmaceutical patentee to establish the manufacturer's intention.

Main arguments relied upon by Ramsay when heard on its application for RAMSAY PHARMACY trade mark.

This sparked interest in the potential for patentees to prevent non-patent infringing generic pharmaceutical products.

It is important to continue to innovate and protect those innovations, even during times of economic difficulty.

IP Australia released new guidance on trade mark classification of emerging technologies, including NFTs and virtual goods.

China updated its Patent Examination Guidelines—effective 1 January 2026—to introduce major revisions, including new rules for AI & Bitstream technologies.

Litigation of unitary patents takes place solely at the Unified Patent Court (UPC).

The Australian Federal Government has indicated that it will seek to introduce permanent reforms in late 2021.

Applicants must ensure that the description of embodiments in a patent specification is updated prior to filing.

Marks using ordinary English words are difficult to register where they are descriptive of relevant goods or services.

The Federal Court of Australia recently refused an application for an interlocutory injunction by Aventis because ten months had elapsed between Aventis’ realisation of allegedly infringing conduct by two generic manufacturers and its subsequent application for injunctive relief from such conduct (Interpharma Pty Ltd v Aventis Pharma SA [2011] FCA 32).

Businesses should avoid adopting trade marks that contain elements that indicate well-known trade marks.

The Court held that the name of a style of bikini was not a trade mark, so infringement proceedings were not warranted.